登录 | 注册    关注公众号  
微信公众号
搜索
 >  Cell>IL-4 R alpha/IL-13 R alpha 1 >CHEK-ATF075

Human IL-4 R alpha/IL-13 R alpha 1 (Luc) HEK293 Reporter Cell

For research use only.

  1. Genetically modified cell lines best reflect MOA (Mechanism of Action)
  2. Higher activity and larger assay window for robust and reproducible cell-based bioassay
  3. Comprehensive application data to support assay development and validation
  4. Full tracible record, stringent quality control and validated cell passage stability
  5. Parental cell line legally obtained from internationally recognized cell resource bank and commercially licensed
  6. Global commercial license assistance whenever regulatory filing is required

描述(Description)

The Human IL-4 R alpha/IL-13 R alpha 1 (Luc) HEK293 Reporter Cell with endogenous IL-4 R alpha and IL-13 R alpha 1 expression was engineered to express STAT6 signaling response element. When stimulated with human IL-4 or IL-13 protein, receptor-mediated signaling can drive STAT6-mediated luminescence. Neutralization of biological effect of human IL-4 or IL-13 protein by corresponding antibody results in a decrease in luminescence.

应用说明(Application)

• Screen for neutralizing antibodies blocking the stimulation of human IL-4 or IL-13 protein.

IL-4 R alpha/IL-13 R alpha 1 Assay Principles

生长特性(Growth Properties)

Adherent

筛选标记(Selection Marker)

Puromycin (2 μg/mL)

培养基(Culture Medium)

DMEM medium + 10% FBS

冻存液(Freeze Medium)

Serum-free cell cryopreservation medium

装量(Quantity)

1 vial contains at least 5×10^6 cells in 1 mL serum-free cryopreservation medium

存储(Storage)

Frozen in liquid nitrogen.

支原体检测(Mycoplasma Testing)

Negative

无菌检测(Sterility Testing)

Negative

使用说明(Instructions for Use)

See data sheet for detailed culturing and assay protocol.

 

Application

IL-4 R alpha/IL-13 R alpha 1 APPLICATION

Inhibition of human IL-4 protein-induced reporter activity by anti-human IL-4 R alpha neutralizing antibody.
This reporter cell was incubated with serial dilutions of antibodies in the presence of human IL-4 protein (Cat. No. IL4-H4218) with a final concentration of 0.002 μg/mL. The EC50 of anti-human IL-4 R alpha neutralizing antibody is approximately 0.0073 μg/mL.

Protocol

IL-4 R alpha/IL-13 R alpha 1 APPLICATION

Inhibition of human IL-13 protein-induced reporter activity by anti-human IL-4 R alpha neutralizing antibody.
This reporter cell was incubated with serial dilutions of antibodies in the presence of human IL-13 protein (Cat. No. IL3-H52H4) with a final concentration of 0.1 μg/mL. The EC50 of anti-human IL-4 R alpha neutralizing antibody is approximately 0.0027 μg/mL.

Protocol

 

Signaling Bioassay

IL-4 R alpha/IL-13 R alpha 1 SIGNALING

Response to human IL-4 protein (RLU).
The Human IL-4 R alpha/IL-13 R alpha 1 (Luc) HEK293 Reporter Cell was stimulated with serial dilutions of human IL-4 protein (Cat. No. IL4-H4218). The EC50 was approximately 0.00043 μg/mL.

Protocol

IL-4 R alpha/IL-13 R alpha 1 SIGNALING

Response to human IL-4 protein (FOLD).
The Human IL-4 R alpha/IL-13 R alpha 1 (Luc) HEK293 Reporter Cell was stimulated with serial dilutions of human IL-4 protein (Cat. No. IL4-H4218). The max induction fold was approximately 43.45.

Protocol

IL-4 R alpha/IL-13 R alpha 1 SIGNALING

Response to human IL-13 protein (RLU).
The Human IL-4 R alpha/IL-13 R alpha 1 (Luc) HEK293 Reporter Cell was stimulated with serial dilutions of human IL-13 protein (Cat. No. IL3-H52H4). The EC50 was approximately 0.077 μg/mL.

Protocol

IL-4 R alpha/IL-13 R alpha 1 SIGNALING

Response to human IL-13 protein (FOLD).
The Human IL-4 R alpha/IL-13 R alpha 1 (Luc) HEK293 Reporter Cell was stimulated with serial dilutions of human IL-13 protein (Cat. No. IL3-H52H4). The max induction fold was approximately 29.36.

Protocol

 

Passage Stability

IL-4 R alpha/IL-13 R alpha 1 PASSAGE

Passage stability analysis by Signaling Bioassay.
The continuously growing Human IL-4 R alpha/IL-13 R alpha 1 (Luc) HEK293 Reporter Cell was stimulated with serial dilutions of human IL-4 protein. Human IL-4 protein stimulated response demonstrates passage stabilization (fold induction and EC50) across passage 5-23.

Protocol

如有相关细胞池需求请联系我们

 

背景(Background)

Interleukin-4 is a key cytokine associated with allergy and asthma. In the presence of IL-4 and IL-13, cytokines that are produced in a Th-2 type response, particularly during allergy and parasitic infections, macrophages become differentially activated, And this cytokine is a ligand for interleukin 4 receptor. The interleukin 4 receptor also binds to IL13, which may contribute to many overlapping functions of this cytokine and IL13. STAT6, a signal transducer and activator of transcription, has been shown to play a central role in mediating the immune regulatory signal of this cytokine. Recently, researcher found that the cytokine IL-4 plays a key role in development of innate CD8+ T cells in the thymus of several gene-deficient mouse strains, including Itk, KLF2, CBP and Id3, without previous exposure to antigen.

 

Limited Use&License Disclosure

  1. This cell line is provided for research use only. It is neither intended for any animal or human therapeutic use nor for any direct human in vivo use. You are restricted to share, modify, transfer, distribute, sell, sublicense, or otherwise make the cell line available for use to other researchers, laboratories, research institutions, hospitals, universities, or service organizations.
  2. ACROBIOSYSTEMS MAKES NO WARRANTIES OR REPRESENTATIONS OF ANY KIND, EITHER EXPRESSED OR IMPLIED, WITH RESPECT TO THE SUITABILITY OF THE CELL LINE FOR ANY PARTICULAR USE.
  3. ACROBIOSYSTEMS ACCEPTS NO LIABILITY IN CONNECTION WITH THE HANDLING OR USE OF THE CELL LINE.
  4. Modifications of the cell line, transfer to a third party, or commercial use of the cell line may require a separate license and additional fees. Please contact order.cn@acrobiosystems.com for further details.

 

前沿进展

 
 
货号/价格
文档
联系电话:
+86 400-682-2521(全国)
010-53681107(北京)
021-50850665(上海)
运输方式
订单邮箱:
order.cn@acrobiosystems.com
技术支持邮箱:
tech.cn@acrobiosystems.com
前沿进展
点击查看详细

消息提示

请输入您的联系方式,再点击提交!

确定